Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Blinklab Limited ( (AU:BB1) ) is now available.
BlinkLab Limited has made significant strides in its clinical trials for autism and ADHD diagnostics. The company has initiated a pivotal FDA 510(k) diagnostic trial for autism in children in the United States, selecting two clinical sites in Ohio and Illinois, and has begun patient recruitment. Additionally, BlinkLab has announced an international collaboration for evaluating its diagnostic tool in adult populations, and is progressing towards a regulatory submission anticipated in early 2026. These developments highlight BlinkLab’s commitment to advancing its diagnostic technology and expanding its scope to address unmet needs in neurodevelopmental and psychiatric conditions.
More about Blinklab Limited
BlinkLab Limited is a leading digital healthcare company specializing in AI-powered diagnostics. The company is focused on developing innovative diagnostic tools for neurodevelopmental and psychiatric conditions, with a market focus on making digitally-assisted diagnosis more accessible globally.
YTD Price Performance: 28.57%
Average Trading Volume: 370,403
Technical Sentiment Signal: Sell
See more data about BB1 stock on TipRanks’ Stock Analysis page.